Tsubota Laboratory Valuation

Is 4890 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 4890 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate 4890's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 4890's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 4890?

Key metric: As 4890 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for 4890. This is calculated by dividing 4890's market cap by their current revenue.
What is 4890's PS Ratio?
PS Ratio	10x
Sales	JP¥1.11b
Market Cap	JP¥11.10b

4890 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	8.9x
Enterprise Value/EBITDA	-70.3x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does 4890's PS Ratio compare to its peers?

The above table shows the PS ratio for 4890 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	17.3x
4582 SymBio Pharmaceuticals	3.6x	n/a	JP¥11.2b
4579 RaQualia Pharma	3.6x	9.6%	JP¥9.9b
4888 Stella Pharma	61.6x	n/a	JP¥17.6b
8095 Astena Holdings	0.4x	n/a	JP¥19.5b
4890 Tsubota Laboratory	10x	n/a	JP¥11.1b

Price-To-Sales vs Peers: 4890 is good value based on its Price-To-Sales Ratio (10x) compared to the peer average (17.3x).

Price to Sales Ratio vs Industry

How does 4890's PS Ratio compare vs other companies in the JP Pharmaceuticals Industry?

3 Companies	Price / Sales	Estimated Growth	Market Cap
4541 Nichi-Iko Pharmaceutical	0.1x	n/a	US$185.57m
8095 Astena Holdings	0.4x	n/a	US$128.88m
4539 Nippon Chemiphar	0.2x	n/a	US$35.92m

No more companies available in this PS range

3 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Sales vs Industry: 4890 is expensive based on its Price-To-Sales Ratio (10x) compared to the JP Pharmaceuticals industry average (1.9x).

Price to Sales Ratio vs Fair Ratio

What is 4890's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

4890 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	10x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate 4890's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Tsumura

JP¥364.3b

Manufactures and sells pharmaceutical products from crude drugs derived from plants and other natural products in Japan and internationally.

4540

JP¥4,797.00

-1.8%

71.5%

Shionogi

JP¥1.8t

Engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan.

4507

JP¥2,125.50

3.2%

-7.2%

ASKA Pharmaceutical HoldingsLtd

JP¥57.2b

Through its subsidiaries, engages in the pharmaceutical, animal health, and hormone testing businesses in Japan.

4886

JP¥2,015.00

-1.3%

11.9%